EPX-HTG for Structural Heart Procedures

A prospective, single-center, clinical chart review. In this trial, we will determine if the additional use of EchoPixel - HTG demonstrates a reduction in procedure time, decrease use of contrast and radiation, minimize the number of devices trialed during a procedure, determine ideal fluoroscopic viewing angles for device deployment, and optimize implant deployment and seal in in Structural Heart (SH) procedures. The study team will compile the redacted pre- procedure CT, redacted procedural Trans-Esophageal Echo (TEE) or Intra-Cardiac Echo (ICE), procedural fluoroscopic imaging and the post device implant imaging created for each procedure case. Patient health information will be redacted and provided to physicians for review. Data will be collected on case report forms. A prospective review will occur of outcomes regarding the Structural Heart (SH) procedure cases and data will be recorded on case report forms to compare to normal historical outcomes. All available consecutive patients treated with the Watchman FLX device for Left Atrial Appendage Occlusion (LAAO) or MitraClip for Mitral Valve transcatheter edge to edge repair (M-TEER) will be reviewed. The primary endpoint will be to determine if EchoPixel - HTG assists in better guiding the implanter during the procedure. All patients 18 and older scheduled for LAAO or M-TEER at the study site and whose procedure will use Philips CVx TEE or 3D ICE. The Primary objective of the study is to determine if adding EchoPixel - HTG has a positive impact on optimal procedure success for patients undergoing an implantation of a Watchman FLX / MitraClip device compared to patients with current SIG. Procedural metrics and any procedural related complications will be recorded as secondary outcomes. Patient demographics blinded procedural outcomes, pre-hospital discharge and complications will be monitored through and until the patient follow-up visit. Study Execution. Collection of data: 1. All patients will be identified using a prospective review. 2. The patients imaging will be de-identified and numbered with randomly picked research subject numbers identified only by site enrollment log (retained at the site only). 3. All deidentified data imaging will be downloaded on the two separate BOX (part 11 FDA compliant) drives. 1. CT data in one drive. 2. TEE data in one drive. 3. ICE data in one drive. 4. All patient's demographics will be obtained (age, ethnicity, vitals, ejection fraction, EKG, hemoglobin, creatinine, medical history, concomitant medications, CHADS2-Vasc, HAS-BLED, primary reason for implant). Analysis of procedural data: 1. Procedure time in minutes. 2. Fluoroscopic time in minutes. 3. Radiation dose in mGy. 4. Contrast used during the LAAO procedure in ml. 5. Number of devices trialed during the LAAO / TEER procedure. 6. Number of attempted device deployments / recaptures. 7. Clinical outcomes and procedural related complications. 8. Composite of procedure-related complications through follow-up visit. Informed Consent Process. This is a prospective trial, utilizing redacted personal health information (PHI). Therefore, consent will be obtained. Privacy, Confidentiality and Data Handling. The investigator will retain all regulatory documents pertaining to this study in compliance with ICH/GCP guidelines. This includes essential study documents and source documentation that support the data collected on the study Subjects. Each subject's study data will be collected and will be securely stored in the coordinating site's office. Subjects will be identified using a subject identification number. Subject information will be anonymized for data analysis. RISKS to PARTICIPANTS. As a prospective study, all patients will be managed according to the practice's standard-of-care. As a result, there are no additional risks to the patients having their medical charts reviewed for this study. Staff and employees at the study site have extensive HIPAA training and all records will be retained at the institution. Data collection will involve the recording of protected health information; however, this PHI data will remain at the study site and only de-identified data will be shared with Echopixel. The Watchman FLX procedure / MitraClip is an FDA approved procedure. BENEFITS to PARTICIPANTS. As an FDA approved device and procedure, there is no direct benefit to the patient. However, information gained from the study will contribute to the body of knowledge regarding the treatment of patients needing the LAAO/MitraClip procedure. Additionally, future patients who may want to consider a LAAO/MitraClip procedure will benefit from the collective published literature base of studies, such as this proposed study.